In rheumatoid arthritis (RA), an alternative to ankle joint arthrodesis is total ankle arthroplasty (TAA). TAA preserves joint motion and function, with protection of other joints ([@CIT0021], [@CIT0004], [@CIT0016]). Currently, the main indications for TAA are end-stage idiopathic, inflammatory, and post-traumatic osteoarthritis ([@CIT0017], [@CIT0019], [@CIT0006]).

During the past 2 decades, medical treatment for RA has improved. Studies from different countries have suggested that rates of joint replacement in RA have decreased in recent years (Da [@CIT0003], [@CIT0009], [@CIT0022], [@CIT0015], [@CIT0023], [@CIT0024], [@CIT0018], [@CIT0014], [@CIT0007]). However, there have only been a few studies on the incidence of ankle joint arthrodesis and TAA in patients with RA ([@CIT0005], [@CIT0013]).

Using data from nationwide population-based registries, we determined the rates of primary ankle joint arthrodesis and TAA in patients with RA in Finland, 1997--2010.

Patients and methods {#ss1}
====================

The annual figures for primary ankle joint (talocrural) arthrodesis were obtained from the Finnish Hospital Discharge Register, based on RA-related diagnosis codes M05--M09 and M45 according to ICD-10 classification, and appropriate surgical procedure codes (NHG20) according the Nordic Medico-Statistical Committee classification. The annual figures for TAA were collected from the Finnish Arthroplasty Register (based on obligatory reports by operating units).

The incidences of primary ankle joint arthrodesis and TAA, and the sum for both operations, were calculated per population of 10^5^ (with respective 95% confidence intervals (CIs), calculated according to Wilson's method).

As the prevalence of rheumatoid arthritis cannot be derived from any nationwide Finnish register, the incidences were calculated for the general population, which makes comparison of incidences between RA and other diagnoses possible. To control for year-to-year variation in operation figures, the incidences were calculated in 2-year periods from 1997 to 2010. The population at the mid-point of each 2-year period was used as denominator in the calculations (derived from the Statistics Finland website, <http://pxweb2.stat.fi/database/StatFin/vrm/vaerak/vaerak_en.asp>). The statistical significance of the temporal trends observed was tested using general linear regression.

Results {#ss2}
=======

During the study period 1997--2010, 593 primary ankle joint arthrodeses and 318 TAAs were performed for patients with RA ([Figure 1](#F1){ref-type="fig"}). Within that time period, the population of Finland increased from 5,114,510 to 5,335,481 (4%).

![The incidence (per 10^5^ of population) of primary ankle joint arthrodesis, total ankle arthroplasty, and the sum of both in patients with RA, in 2-year periods from 1997 to 2010 (with 95% CIs).](ORT-84-338-g001){#F1}

Primary ankle joint arthrodesis {#ss3}
-------------------------------

While total ankle replacement surgery became more common, the number of primary ankle joint arthrodeses in patients with RA decreased. In 1997--1998, the incidence of primary ankle joint arthrodesis was 2.4/10^5^ (CI: 2.0--2.8) and in 2001--2002 the incidence was lowest, 1.1/10^5^ (CI: 0.8--1.4). After 2002, it increased slightly, although no statistically significant difference was observed and it did not reach the level of 1997--1998, even though by 2009--2010 the use of TAAs had almost ended.

Total ankle arthroplasty {#ss4}
------------------------

During the study period, one third of all TAAs in Finland were undertaken due to RA. These were performed in 14 hospitals; annually, only 1 or 2 hospitals performed more than 10 replacements. Altogether, 5 different implants were used: the LINK S.T.A.R. (Waldemar Link, Hamburg, Germany), the AES (Ankle Evolutive System, Valence, France), the Mobility (DePuy, Warsaw, IN), the Hintegra (Newdeal, Lyon, France), and the CCI (Van Straten Medical, the Netherlands). In 2003, there was a shift from the commonly used LINK S.T.A.R. prosthesis to the AES prosthesis.

Since 1997, the numbers of TAAs in patients with RA increased (p \< 0.001) until 2003--2004 (incidence 1.5/10^5^, CI: 1.3--1.9) and then gradually decreased (p = 0.001). In 2009--2010, the incidence of TAA was only 0.4/10^5^ (CI: 0.3--0.7). The incidence of TAA performed due to any diagnosis followed a similar pattern ([Figure 2](#F2){ref-type="fig"}).

![The incidence (per 10^5^ of population) of total ankle arthroplasty in patients with RA and in patients with any diagnosis (including RA), in 2-year periods from 1997 to 2010.](ORT-84-338-g002){#F2}

Regression analysis confirmed the statistical significance of the declining trend in the incidence of primary ankle arthrodesis in patients with RA from 1997 to 2010 (p = 0.04), whereas no change was observed in the total incidence of ankle surgery in patients with RA (primary arthrodesis and TAA, pooled) (p = 0.226).

Discussion {#ss5}
==========

The Finnish Hospital Discharge Register does not contain information on disease onset and disease duration in RA patients. However, since 1995 the Finnish Arthroplasty Register data have been synchronized with the Discharge Register every few years, and currently over 95% of implantations are recorded ([@CIT0019]).

By reason of changes in the classification of diagnoses and surgical procedures in the Hospital Discharge Register in 1997, we could not analyze data on arthrodeses from earlier years. Indications for TAA and ankle joint arthrodesis are not entirely consistent. In most severe cases of ankle joint destruction, TAA may be technically impossible and ankle arthrodesis must be used.

Previously, [@CIT0005] reported that in Norway during 1994--2004 the incidence of arthroplasty of the foot had decreased, whereas the opposite was true for arthrodesis of the ankle/foot with chronic inflammatory joint disease. We found a decrease in incidence for total ankle arthroplasties in patients with RA since 2003--2004, and a slight increase in the incidence of primary ankle joint arthrodesis since 2001--2002, but the increase was not statistically significant.

In their study of patients on RA in California 1983--2007, [@CIT0013] found that the rates of ankle surgery (arthrodesis and arthroplasty, pooled) peaked in the mid-1990s. Thereafter, the rates decreased and the relative risk of operative treatment was one third lower in 2003--2007 than in 1983--1987. At the end of our observation period, the numbers of ankle operations (arthrodesis and TAA, pooled) decreased due to the steep drop in TAA surgery.

The first-generation total ankle prostheses were abandoned in the 1980s and 1990s due to unacceptable failure and complication rates ([@CIT0002], [@CIT0004]). In 1997, a new 3-component design was introduced in Finland and the number of total ankle replacements increased while the numbers of ankle arthrodeses began to decrease. Remarkably, during the study period 5 different implants were used and TAA surgery was done in several hospitals; only a few hospitals performed more than 10 operations annually. Our opinion, although not supported by the present data, is that ankle prosthesis surgery in patients with RA should be centralized to a few hospitals in Finland to give an adequate number of operations per unit and surgeon in order to ensure repetition and quality ([@CIT0012]).

At the end of the study period 2008--2010, complications were seen with the AES prosthesis as a result of osteolysis ([@CIT0010], [@CIT0011]). These observations rapidly changed the practice, and total ankle replacement surgery was almost completely abandoned in Finland. This applied both to TAAs performed for RA and to those performed for other diagnoses. Thus TAAs radically decreased whereas, interestingly, the incidence of ankle joint arthrodesis in patients with RA did not increase.

In Finland, the incidence of rheumatoid factor-positive RA decreased in 1980--2000 ([@CIT0008]), but at the moment there is no published evidence of a changing incidence of RA. At the same time, current care guidelines advocate active treatment of RA using drug combinations, and the number of patients receiving anti-rheumatic drugs has increased (The drug registers of the Social Insurance Institution of Finland). This change in the management of RA has been considered to be a major factor underlying the decrease in the rates of hip, knee, elbow, and shoulder replacements ([@CIT0007]).

Thus, we can only speculate on what will happen in future. Anti-rheumatic agents will probably reduce the need for ankle surgery, due to the prevention of ankle joint destruction. New prosthesis designs will be developed with expectations of better survival rates.

However, the ankle joint (talocrural) is involved at a late stage of RA and is usually affected only in patients with severe disease ([@CIT0001]). Thus, a longer-term follow-up will be required to explain how improved medical therapy, particularly biological, influences the risk of ankle joint destruction, and whether there are any changes in epidemiology that would affect the need for ankle surgery in RA.

In conclusion, during the observation period 1997--2010, while total ankle replacements became generally more common in patients with RA, the incidence of primary ankle joint arthrodesis decreased and did not increase in 2009--2010, even though total ankle replacement surgery almost ended in Finland. When the data were pooled together, no change in the incidence of these operations was observed in the period 1997--2010.
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